Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.47 |
| ▸ | GRIN2B known ✓ | Q13224 | 3/20 | 0.46 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.44 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29711570 | 1.00 | KDM1A (0.49) | KDM1ADPP4GRIN2BMAPTCA1 | |
| SCHEMBL29378921 | 0.98 | KDM1A (0.50) | KDM1ADPP4GRIN2BMAPTCA1 | |
| SCHEMBL399565 | 0.98 | KDM1A (0.50) | KDM1ADPP4GRIN2BMAPTCA1 | |
| SCHEMBL12656430 | 0.87 | GRIN2B (0.56) | DPP4GRIN2BCA1CA2MTNR1A | |
| Hydrochloric Acid SCHEMBL10493696 | 0.84 | GRIN2B (0.51) | DPP4GRIN2BMAPTMTNR1AMTNR1B | |
| SCHEMBL29434614 | 0.81 | GRIN2B (0.53) | DPP4GRIN2BMAPTMTNR1AMTNR1B | |
| SCHEMBL255286 | 0.81 | GRIN2B (0.53) | DPP4GRIN2BMAPTMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL7144380 | 0.81 | OPRM1 (0.45) | KDM1ADPP4CA1CA2GRM7 | |
| SCHEMBL13846495 | 0.81 | GRIN2B (0.55) | DPP4GRIN2BMAPTCA1CA2 | |
| Bicarbonate SCHEMBL2441660 | 0.80 | GRIN2B (0.51) | DPP4GRIN2BMAPTMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| US-10894069-B2 | Topical antiviral formulations and methods of using the same | MCELVANY CHRISTOPHER A (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200319110-A1 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE | RAMAN HEALTH TECHNOLOGIES, S.L. (ES) | 2020-10-08 | — | — | US | disclosed |
| US-20200230187-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | MCELVANY CHRISTOPHER A (US) | 2020-07-23 | — | — | US | disclosed |
| US-10456435-B2 | Topical antiviral formulations and methods of using the same | MCELVANY, Christopher A. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3465163-A1 | METHOD FOR DIAGNOSING ALZHEIMER´S DISEASE | Raman Health Technologies, S.L (ES) | 2019-04-10 | — | — | EP | disclosed |
| US-20180207213-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | MCELVANY, CHRISTOPHER | 2018-07-26 | — | — | US | disclosed |
| WO-2017202779-A1 | METHOD FOR DIAGNOSING ALZHEIMER´S DISEASE | RAMAN HEALTH TECHNOLOGIES, S.L (ES) | 2017-11-30 | — | — | WO | disclosed |
| EP-3249388-A1 | METHOD FOR DIAGNOSING ALZHEIMER´S DISEASE | Raman Health Technologies, S.L (ES) | 2017-11-29 | — | — | EP | disclosed |
| WO-2017011785-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | NATIONAL CONCESSIONS GROUP INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-12-04 | — | — | US | disclosed |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-11-27 | — | — | US | disclosed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD | 2008-03-13 | — | — | US | disclosed |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| EP-1455771-B1 | 2-INDANYLAMINO DERIVATIVES FOR THE THERAPY OF CHRONIC, ACUTE OR INFLAMMATORY PAIN | CHIESI FARMA SPA (IT) | 2006-11-08 | — | — | EP | disclosed |
| EP-1321139-B1 | 2-Indanylamino deratives for the therapy of chronic, acute or inflammatory pain | CHIESI FARMA SPA (IT) | 2006-08-23 | — | — | EP | disclosed |
| EP-0951465-B1 | ALPHA-AMINO ACID AMIDES, PREPARATION THEREOF AND THE THERAPEUTICAL USE THEREOF | CHIESI FARMA SPA (IT) | 2003-04-16 | — | — | EP | disclosed |
| US-6114391-A | A DERIVATIVES OF SERINAMIDE, GLYCINAMIDE, ALANINAMIDE AND PHENYLALANINAMIDE FOR TREATING NEUROLOGICAL DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | DPP4 3814/4885GRIN2B 4628/4885CA2 4104/4885 |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | SSTR2, SSTR3, LPXN | DPP4 4837/4885GRIN2B 4345/4885CA2 3435/4885 |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | DPP4 4491/4885GRIN2B 4493/4885CA2 3398/4885 |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | DPP4 4491/4885GRIN2B 4493/4885CA2 3398/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | DPP4 4073/4885GRIN2B 158/4885CA2 352/4885 |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | LIPA, PHOSPHO1, MYO1G | DPP4 4668/4885GRIN2B 2884/4885CA2 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.